Page 8 - ஹாஃப்மேன் எஸ்டேட் தெற்கு ரிட்ஜ் பூங்கா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஹாஃப்மேன் எஸ்டேட் தெற்கு ரிட்ஜ் பூங்கா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஹாஃப்மேன் எஸ்டேட் தெற்கு ரிட்ஜ் பூங்கா Today - Breaking & Trending Today

Schistosome Study reveals Potential for Drug target Discovery


Feb 12 2021 Read 1116 Times
A study into the basic biology of parasitic flatworms known as schistosomes has revealed potential weaknesses in their biology which could lead to new treatments for a tropical disease estimated to kill up to 250,000 people every year.
Schistosomiasis, affecting mostly children in Africa, Asia and South America, leads to organ failure or parasite-induced cancer and can leave victims with long term symptoms of chronic infection.
The work(1) has been led by Dr James Collins III’s team at the University of Texas Southwestern (UTSW) with Dr Matthew Berriman’s group at the Wellcome Sanger Institute offering genome support and Professor Karl Hoffmann and Dr Gilda Padalino at Aberystwyth University providing key validation experiments. ....

United States , United Kingdom , Karl Hoffmann , Matthew Berriman , Dr Gilda Padalino At Aberystwyth University , University Of Texas Southwestern , Wellcome Sanger Institute , South America , Texas Southwestern , Professor Karl Hoffmann , Aberystwyth University , Professor Hoffmann , Wellcome Trust , South Western , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , கார்ல் ஹாஃப்மேன் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் தென்மேற்கு , வெல்கம் சாங்கர் நிறுவனம் , தெற்கு அமெரிக்கா , டெக்சாஸ் தென்மேற்கு , ப்ரொஃபெஸர் கார்ல் ஹாஃப்மேன் , ப்ரொஃபெஸர் ஹாஃப்மேன் , வெல்கம் நம்பிக்கை , தெற்கு மேற்கு ,

Hoffmann Green Cement Technologies Reaffirms Its Environmental and Social Strategy and Has Been Positively Assessed by Extra-Financial Rating Agencies


Hoffmann Green Cement Technologies Reaffirms Its Environmental and Social Strategy and Has Been Positively Assessed by Extra-Financial Rating Agencies
Hoffmann Green or the
Company ), a pioneer in clinker-free low-carbon cement, has obtained positive assessments from independent players specializing in extra-financial ratings, validating its environmental and social strategy.
Ever since its creation, Hoffmann Green s goal has been to decarbonize the construction sector by producing and marketing clinker-free low-carbon cement whose carbon footprint is five times lower that of traditional cement. In 2020, Hoffmann Green formalized a global CSR approach and has now obtained a number of positive assessments that illustrate the Company s commitment in this respect. ....

Bilan Carbone , David Hoffmann , Pierre Laurent , Nicolas Merigeau , Thomas Grojean Quentin , Julien Blanchard , Net Zero Initiative , Regulatory News , Green Cement Technologies , Hoffmann Green , Hoffmann Green Cement Technologies , Net Zero , Hoffmann Green Cement Technologie , Carbon Disclosure Project , Social Governance , Financial Officer , Quentin Mass , பிலன் கார்போன் , டேவிட் ஹாஃப்மேன் , பியர் பரிசு பெற்றவர் , ஜூலியன் பிளான்சார்ட் , நிகர பூஜ்யம் முயற்சி , ஒழுங்குமுறை செய்தி , பச்சை சிமென்ட் தொழில்நுட்பங்கள் , ஹாஃப்மேன் பச்சை , ஹாஃப்மேன் பச்சை சிமென்ட் தொழில்நுட்பங்கள் ,

F. Hoffmann-La Roche Ltd: FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients


(2)
FDA BDD acknowledges the importance of GDF-15 testing in identifying eligible cachexic patients with solid tumours to be treated with Pfizer s investigational drug PF-06946860
Unintentional weight loss (cachexia) is a highly prevalent complication of cancer, affecting more than half of all cancer patients worldwide, potentially leading to significant functional impairment and increased risk of death
Successful cachexia treatment can potentially contribute to improved cancer treatment worldwide
Basel, 8 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to their Elecsys GDF-15 assay as a companion diagnostic (CDx) in cancer treatment. This in vitro diagnostic immunoassay is intended for measurement of Growth Differentiation Factor-15 (GDF-15) in cachectic patients 18 years of age and older with solid tumours for treatment with Pfizer Inc. s (NYSE: PFE) in ....

United States , Nathalie Meetz , Jon Kaspar Bayard , Daniel Grotzky , Karl Mahler , Sabine Borngr , Gerard Tobin , Bruno Eschli , Birgit Masjost , Loren Kalm , Lisa Tuomi , Thomas Schinecker , Patrick Barth , Karsten Kleine , Drug Administration , Pfizer Inc , Roche Group , Pharmaceuticals Industry , Roche Group Media Relations , Breakthrough Device Designation , Growth Differentiation , World Health Organization Model Lists , Essential Medicines , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Nature Reviews ,